Virtual Library

Start Your Search

Catherine Labbe



Author of

  • +

    P1.04 - Immuno-oncology (ID 164)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.04-01 - Body Mass Index and Age Do Not Influence Survival in Patients with Lung Cancers Treated with PD1/PDL1 Immune Checkpoint Inhibitors (ID 2333)

      09:45 - 18:00  |  Author(s): Catherine Labbe

      • Abstract

      Background

      Age and body mass index (BMI) are important factors in patients treated with chemotherapy. However, in the era of immune checkpoint inhibitors (ICI), the importance of these baseline characteristics is unclear. For example, pooled analysis of age did not influence the clinical response to ICI, whereas patients with BMI >35 had better outcomes in melanoma and renal cell carcinoma. More data are needed to clarify the role of these two characteristics in non-small cell lung cancer (NSCLC) patients amenable ICI.

      Method

      We conducted a retrospective analysis of patients treated with anti-PD1 ICI for advanced NSCLC at the Dijon Cancer Center (n=177), University of Montreal University Hospital (n=106) and Quebec Heart and Lung Institute (n=98). BMI and age were considered as continuous or categorical variables. Patients’ baseline characteristics were compared using the Chi-squared test. Survival curves were estimated by the Kaplan-Meier method and compared with the Log-rank test in a univariate analysis. Multivariate cox regression model was used to determine hazard ratios and 95% confidence intervals for progression-free survival (PFS) and overall survival (OS) between the groups, adjusting for other clinicopathologic features.

      Result

      Among 381 patients included, the median BMI was 24.5 (range 16.2-43.4) and 32.7% and 13.6% were classified as overweight or obese respectively. The median age was 66 (range 37-89) and 29% were older than 70 years-of-age. Considering BMI and age as continuous or categorical variables, they were not associated with PFS or OS, with the exception of BMI in the Dijon cohort (continuous: HR=0.95, 95%CI[0.91-0.99]; < 25 vs > 25: HR=0.68, 95%CI[0.47-0.99]). Subgroup analysis and multivariate cox regression did not reveal significant interaction of these two factors with outcomes. There was no difference in toxicity between the groups. ECOG performance status was the only significant factor in the three cohorts.

      Conclusion

      Unlike previously described in the era of chemotherapy, obesity and age were not associated with outcomes in NSCLC patients treated with ICI.

  • +

    P1.18 - Treatment of Locoregional Disease - NSCLC (ID 190)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment of Locoregional Disease - NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.18-17 - Survival After Adjuvant Chemotherapy in Completely Resected N1 Non-Small Cell Lung Cancer (Now Available) (ID 368)

      09:45 - 18:00  |  Author(s): Catherine Labbe

      • Abstract
      • Slides

      Background

      Upfront surgery is the standard of care for patients with clinical stage I or II non-small cell lung cancer (NSCLC), but the relapse rate remains high, and 5-year survival is unsatisfactory. Randomized controlled trials, including the International Adjuvant Lung Cancer trial published in 2014, showed that adjuvant chemotherapy (ACT) after surgery increased overall survival at 5 years. However, ACT is seldom well tolerated, and often patients do not complete treatment. The goal of this study was to analyze the effects of adjuvant therapy in patients with N1 disease to better understand the effectiveness of ACT in a real-world surgery series.

      Method

      This is a retrospective study from a prospectively maintained database at our institution. Patient with NSCLC were included in the study if they underwent surgery with complete resection (R0) from January 2006 to December 2017 and had pathological N1 NSCLC.

      Result

      We identified 207 patients with pN1 NSCLC; their mean age was 64.5 ± 8.9 years. Most (71.2%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0. Eight patients (3.9%) were never-smokers. Over 50% of the patients had a video-assisted thoracoscopic surgery (VATS) lobectomy. Mean tumor size was 31.6 ± 15.4 mm, and most tumors (70.5%) were adenocarcinomas. Although 139 patients (65.7%) underwent ACT using the BR.10 chemotherapy regimen, only 59 patients (42.4%) completed all cycles of the treatment. Five years after surgery, overall survival was 55±4%, and disease-free survival was 39.3±4%. There was no statistically significant difference in disease-free survival between the patients who received ACT and those who did not (median 4.0 vs 2.8 years, hazard ratio [HR] = 0.74 (95% confidence interval, 0.49, 1.11), p = 0.1463), but there was a trend toward improved overall survival in patients who underwent ACT (median 8.6 vs 5.0 years, HR = 0.66 (0.41, 1.05), p = 0.0763). (Figure 1)

      Conclusion

      Adjuvant chemotherapy was completed in only 42% of patients in this single-center, retrospective study. No statistically significant differences in disease-free survival or overall survival as a result of ACT were observed, likely a result of the small cohort. This study highlights the difficulties patients encounter in completing ACT, and the need for alternative ACT regimens to improve survival in patients with pN1 NSCLC after surgery.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    WS04 - Staging Workshop Part 1: IASLC Database Challenges and Application (ID 105)

    • Event: WCLC 2019
    • Type: Workshop
    • Track: Staging
    • Presentations: 1
    • Now Available
    • +

      WS04.04 - Institutional Benefits of Adherence to IASLC Database (Now Available) (ID 3681)

      14:00 - 15:30  |  Presenting Author(s): Catherine Labbe

      • Abstract
      • Presentation
      • Slides

      Abstract

      The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, through an electronic data capture system, is a global effort to study and improve the current and future lung cancer staging system. In 2016, the 8thedition of the TNM was developed with the participation of 35 centres from 16 countries. In 2018, the Heart and Lung Institute in Quebec City, Canada, started to collect and send data for the upcoming 9thedition of the TNM classification.

      The purpose of this presentation is to review and discuss the potential institutional benefits of adherence to the IASLC electronic database, namely the comprehension by all participating centers of the role and the importance of the database, the organization of an interdisciplinary group to ensure that the entire clinical pathway of lung cancer patients is evidence-based, the standardisation of radiology and pathology reports, and the improvement in rates of lobe-specific systematic nodal dissection for all lung resections.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.